Kornimate/medical-research-clean huggingface dataset:
the efficacy of hepatic arterial infusion chemotherapy (haic) combine lenvatinib and durvalumab (hill) in advanced hepatocellular carcinoma (hcc)

Conditions: Hepatocellular Carcinoma

Summary: to evaluate the efficacy of haic combine lenvatinib and durvalumab (hill) in advanced hcc.


Eligibility criteria:
inclusion criteria: * older than 18 years old and younger than 75 years; ecog ps≤1; proven advanced hepatocellular carcinoma according patological examination or easl/aasld diagnostic criteria; not previous treated for tumor; cannot accepted hepatectomy; the lab test could meet: neutrophil count≥2.0×109/l; hemoglobin≥100g/l; platelet count≥75×109/l; serum albumin≥35g/l; total bilirubin\<2-times upper limit of normal; alt\<3-times upper limit of normal; ast\<3-times upper limit of normal; serum creatine\<1.5-times upper limit of normal; pt≤upper limit of normal plus 4 seconds; inr≤2.2; sign up consent; exclusion criteria: * cannot tolerate haic or lenvatinib or durvalumab; known history of other malignancy; be allergic to related drugs; underwent organ transplantation before; be treated before (interferon included); known history of hiv infection; known history of drug or alcohol abuse; have gi hemorrhage or cardiac/brain vascular events within 30 days; pregnancy;
the cutoff point for caval index and its correlation with central venous pressure and plasma lactate level for assessing patients in hypovolemic hemorrhagic states

Conditions: IVC Collapsibility Index; Hemorrhagic Shock

Summary: the purpose of this study is to determine the cutoff point for ivc collapsibility index (by bedside ultrasonographic technique) for cases in hypovolemic hemorrhagic shock with cvp measures less than 8 cmh2o.


Eligibility criteria:
inclusion criteria: * hypovolemic hemorrhagic subjects (class ii or more)if they were more than 18 years old and cvc insertion was indicated for them. exclusion criteria: * a history of renal failure, congestive heart failure, use of negative inotropic agents, presence of any contraindication for cvc insertion or failed ones and inability for measuring ivc by bus were considered for exclusion.

Keywords: ivc ultrasonography ivc collapsibility index ivc diameter
personalized therapy study - intrinsic antitachycardia pacing post-approval study (iatp pas)

Conditions: Ventricular Tachycardia

Summary: medtronic is sponsoring the intrinsic antitachycardia pacing post-approval study (iatp pas) to further confirm safety and effectiveness of ventricular iatp therapy in routine clinical practice, following commercial release of iatp-capable devices. the iatp pas is conducted within medtronic's product surveillance registry platform (nct01524276).

the iatp pas is a global, prospective, observational, multi-site registry study. patients enrolled in the iatp pas will be prospectively followed in the registry until registry closure, patient death, or patient exit from the registry (i.e., withdrawal of consent). patient and device status will be assessed at least annually or as prompted by reportable adverse events. remote device data transmissions are recommended to occur at least quarterly. primary objective analysis will occur when 241 iatp-treated eligible ventricular episodes in the fast ventricular tachycardia (fvt) zone have been collected and reviewed by the study episode review committee (erc). the total study duration is approximately 5 years.

Eligibility criteria:
inclusion criteria: * patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements * patient is intended to receive or is implanted with an iatp-capable device with iatp on in any zone with ventricular atp therapies programmed. * patient is enrolled in the carelink network for remote device monitoring exclusion criteria: * patient who is, or is expected to be inaccessible for follow-up * patient with exclusion criteria required by local law * patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound results
relation between aortic sclerosis &severity of coronary heart disease.

Conditions: Aortic Valve Sclerosis

Summary: the goal of the study to identify the relation between aortic valve sclerosis and severity of coronary heart disease by performing transthoracic echo doppler study for severity of aortic valve sclerosis in patient will undergo coronary angiography with calculation of syntax score as a tool for severity of coronary heart disease.


Eligibility criteria:
inclusion criteria: * aortic sclerosis diagnosed by trans thoracic echo doppler exclusion criteria: * patients who known to be rumatic heart disease or congenital aortic valve disease.
can pregnancy be predicted according to atr-ftir spectrophotometry of incubation medium of embryos in ivf

Conditions: Infertility

Summary: the aim of this study is to examine the variability of culture media composition based on the atr-ftir (attenuated total reflectance-fourier transform infrared spectroscopy) technique on the day of embryo transfer/vitrification. in addition, the study will explore whether variations detected in the culture medium can be linked to embryo quality and the chances of achieving pregnancy.


Eligibility criteria:
inclusion criteria: * women undergoing ivf treatments with at least 4 embryos exclusion criteria: -
adenoma detection rate in colonoscopy performed with endorings

Conditions: Colorectal Adenoma; Colorectal Neoplasms

Summary: the study is designed to examine whether colonoscopy using an endorings cap has a higher adenoma detection rate than conventional colonoscopy. secondary end-points is to compare completion rate, completion time, complication rate and detection of malignancies. half of the patients will be randomised to colonoscopy using cap and the other half to no cap.

colonoscopy is recognised as the standard method for finding and removing colorectal adenomas, which are precursors of most colorectal cancers. it has been shown that there is a direct correlation between adenoma detection rate and the risk of developing colorectal cancer subsequently. however, patients undergoing colonoscopy are still at risk of developing colorectal cancer, mainly because precursor lesions are missed during the procedure. this may be due to insufficient bowel preparation, difficulties in visualising flat lesions or the location of lesions behind haustral folds. improving the adr can be achieved by different means; better training of endoscopists, improved bowel preparation, optimal sedation and medico technical developments. the technical improvements have mainly been in the optimising of image and improved scope thickness and flexibility, including devices that improve visualisation by increasing the exposed colonic surface . one of these new inventions is the endorings ii distal attachment. according to the danish colorectal cancer screening database, the adr of standard screening colonoscopy is between 34 and 67 % with a national average of 49 % of patients with detected adenomas. due to the known adenoma miss rate in standard screening colonoscopies, it is important to increase the adr on average as well as finding ways to improve adr for centres with a lower than average adr.

Eligibility criteria:
inclusion criteria: patients meeting all the below listed criteria are eligible for inclusion in the trial: 1. age between 50 - 74 years (age range of screening population) 2. positive hemocult home test from the danish colorectal cancer screening programme 3. ability to give informed consent to participation in the trial. exclusion criteria: patients meeting one or more of the below listed criteria will be excluded from the trial: 1. history of colorectal cancer 2. history of inflammatory bowel disease 3. part of other control programme (e.g. hnpcc or adenoma control) 4. asa =/\> 4 and/or necessity of general anaesthesia 5. former surgery with removal of a part of the colon on either benign or malignant background

Keywords: colorectal adenoma colonoscopy caps adenoma detection rate
remote ischemic preconditioning in elective percutaneous interventions

Conditions: Myocardial Ischemia; Ischemic Reperfusion Injury

Summary: myocardial injury occurs after percutaneous coronary intervention due to micro emboli, ischemia-reperfusion injury or side branch occlusion. 3 cycles of ischemic preconditioning has been shown to be useful in preventing myocardial injury but it is not suitable to perform it especially in ad hoc interventions. in this study the investigators aim is to show whether one cycle remote ischemic preconditioning will be enough to prevent myocardial injury during percutaneous coronary intervention.

about in one third of elective percutaneous coronary interventions (pci) troponin release occurs showing myocardial necrosis. and it has been shown that myocardial necrosis due to coronary interventions has also adverse effects on long term prognosis. beneficial effects of of ischemic preconditioning in elective pci and in coronary artery bypass surgery has been shown in several studies. in most of the trials 3 cycles of ischemia was performed, but this is time consuming and it's not suitable to apply it, in ad-hoc interventions. the investigators found one study showing that one cycle will also be enough to prevent troponin elevation after elective pci. the investigators aim was also to show that one cycle preconditioning performed just before coronary intervention will also be useful in preventing myocardial necrosis due to elective pci.

Eligibility criteria:
inclusion criteria * patients with stable coronary artery disease, in whom percutaneous coronary intervention is planned after coronary angiography * patients with informed consent exclusion criteria: * acute or chronic renal failure (creatinin clearance \<60ml/dk) * acute heart failure * presence of hemodynamic instability * left main interventions * acute coronary syndrome * patients in whom cuff inflation is contraindicated in upper extremities (fistula, lymphoedema etc) * patients using nicorandil, glibenclamide or trimetazidine * patients not accepting the study * presence of troponin elevation before intervention * presence or suspicion of pregnancy

Keywords: ischemic preconditioning myocardial injury percutaneous coronary intervention
treatment of non-tuberculous mycobacterial infections with interferon gamma

Conditions: Healthy; Mycobacterium Infections, Atypical

Summary: this is an open label study to determine the effects of the administration of interferon-gamma on the clinical condition and immune function of patients with severe, treatment refractory non-tuberculosis mycobacterial infections. the study drug (interferon gamma) will be administered subcutaneously three times a week at 0.05 mg/m(2) for one year. we may also collect blood from the relatives of these patients and normal volunteers in order to characterize the genetic basis, if any, of our patients' disorders.

this is an open label study to determine the effects of the administration of interferon-gamma on the clinical condition and immune function of patients with severe, treatment refractory non-tuberculosis mycobacterial infections. the study drug (interferon gamma) will be administered subcutaneously three times a week at 0.05 mg/m(2) for one year. we may also collect blood from the relatives of these patients and normal volunteers in order to characterize the genetic basis, if any, of our patients' disorders.

Eligibility criteria:
demonstrated non-tuberculous mycobacterial infection, either disseminated or pulmonary. received medical treatment for at least 3 months without improvement. preserved renal, hepatic and hematologic function. negative pregnancy urine and effective contraceptive. age range greater than 5. no secondary immunodeficiency such as hiv or malignancy. not currently receiving cytotoxic therapy within the past 3 months. not pregnant or lactating. no seizure disorders. no known symptomatic cardiac disease.

Keywords: immune adjuvant phagocytes non-tuberculous mycobacterial infection
erectile rating during the treatment of rectal cancers localized

Conditions: Rectal Cancer Stage I

Summary: erectile dysfunction will be explored by recording r / p and self-administered questionnaire iief-5.

erectile dysfunction will be explored by recording r / p and self-administered questionnaire iief-5. this dual evaluation will be made before the beginning of the therapeutic treatment and 3 months and 12 months after surgery. assessed by iief-5 will be made only 6, 18 and 24 months after surgery. there will be no changes made to support oncology patients.

Eligibility criteria:
inclusion criteria: 1. male patient. 2. age greater than 18 years. 3. neoplastic rectal stage ≤ t3. 4. patient sexually active before diagnosis. 5. laparoscopic surgery. 6. medico-surgical institute bergonié. 7. patient information and consent for participation in the study. exclusion criteria: 1. patients already treated for erectile dysfunction. 2. absence of sexual activity before diagnosis. 3. presence of secondary lesions at diagnosis (m +). 4. classified t4 tumor preoperatively. 5. surgery by laparotomy. 6. history of pelvic cancer surgery prostate or bladder. 7. history of pelvic radiotherapy (outside of the current process). 8. history of prostate or bladder neoplasia known. 9. other neoplastic known. 10. patient for psychological, social, family or geographical could not be treated or monitored regularly according to the criteria of the study, patient deprived of liberty or under guardianship.

Keywords: localized rectal cancer in a male patient
clinical analysis of naxitamab (hu3f8) in the treatment of pediatric high risk or refractory/ relapsed neuroblastoma

Conditions: Neuroblastoma

Summary: this is an prospective study to evaluate the safety and efficacy of naxitamab monotherapy or combined with chemotherapy or combined with chemotherapy and checkpoint inhibitor in the treatment of pediatric high-risk and refractory/relapsed neuroblastoma in sun yat-sen university cancer center.

patients with high risk neuroblastoma who obtain cr after chemotherapy combined with surgery, radiotherapy and/or hematopoietic stem cell transplantation received axitamab and gm-csf. patients with high-risk neuroblastoma treated by chemotherapy combined with surgery, radiotherapy and or hematopoietic stem cell transplantation patients with tumor residual or progression during treatment (refractory) received naxitamab and gm-csf in combination with irinotecan and temozolomide or naxitamab and gm-csf in combination with irinotecan and temozolomide and pd-1 antibody.

Eligibility criteria:
inclusion criteria: 1)confirmed diagnosis of high-risk nb 2)1 year of age or above 3)patient or parent/guardian must provide written informed consent to participate 4)if patient is sexually active, the patient agrees to use effective contraception 5)confirmed negative urine pregnancy test for sexually active female of child-bearing potential (post-menarche) exclusion criteria: 1. significant organ toxicity 2. known or suspected allergy or hypersensitivity to anti-gd2 antibodies or to gm-csf or its s components. 3. patient is pregnant, planning to become pregnant (while being treated with naxitamab) or is currently breastfeeding 4. patient will undergo treatment with another investigational drug, whilst being treated with naxitamab or has received another investigational drug within the 4 weeks prior to commencing treatment with naxitamab 5. patient is either eligible and able to participate in or is currently participating in an active interventional y-mabs sponsored clinical trial with naxitamab within the indication applied for 6. patient is unable to comply with the naxitamab treatment or has a medical condition that would potentially increase the severity of the toxicities experienced from naxitamab treatment at the discretion of the treating physician 7. left ventricular ejection fraction of \<50% by echocardiography or other clinically relevant cardiac disorders at the discretion of the investigator 8. inadequate pulmonary function defined as evidence of dyspnea at rest, exercise intolerance, and/or chronic oxygen requirement. in addition, room air pulse oximetry \< 94% and/or abnormal pulmonary function tests if these assessments are clinically indicated applicable for treatment with naxitamab in combination with gm-csf only: 9. patient has active progression of the nb disease 10. patient has active nb disease at primary site or soft-tissue metastasis 11. patient has known cns metastases when initiating naxitamab treatment
covid-19 quarantine on musculoskeletal status in hemophilia

Conditions: Hemophilia Arthropathy

Summary: background. the recurrence of hemarthrosis in patients with congenital coagulopathies favors the development of a progressive, degenerative and intra-articular lesion (hemophilic arthropathy) that mainly affects the knees, ankles and elbows. pain is one of the main clinical manifestations of hemophilic arthropathy. as a consequence of the covid-19 pandemic, the government of spain, among others, established a total confinement for two months, in order to avoid contagion of the population objective. to assess the effect of covid-19 confinement on bleeding frequency, pain perception, and range of motion in patients with hemophilic arthropathy. study design. prospective observational study. method. 27 patients with hemophilia a and b will be included in this study. patients will be recruited from the spanish hemophilia federation (fishemo) specialized center for hemophilia patients. the dependent variables will be: the frequency of bleeding (through a self-report), the perception of pain (measured with the visual analog scale and a pressure algometer), the joint state (with the hemophilia joint health score), and the range of joint movement (measured with a goniometer). two evaluations will be carried out: pre-treatment (carried out in the month of february, as a periodic evaluation) and post-treatment (at the end of the period of confinement in spain). expected results. the aim is to observe the sequelae caused by confinement and a sedentary lifestyle in patients with hemophilic arthropathy, through changes in joint status, pain and range of motion.


Eligibility criteria:
inclusion criteria: * patients with medical diagnosis of hemophilia a or hemophilia b * patients over 18 years of age * patients in a prophylactic or on demand regimen with factor viii / factor ix concentrates * patients that have accepted the informed consent document. exclusion criteria: * patients with neurological or cognitive disorders that prevent the comprehension of the questionnaires * patients without capacity to walk autonomously or with orthosis * patients without access to digital media to complement the measuring instruments.

Keywords: hemophilic arthropathy joint pain joint health range of motion hemarthrosis covid-19
dietary intervention with únicla dairy products (dantian)

Conditions: Subclinical Hypothyroidism

Summary: dietary intervention with únicla dairy products, naturally enriched with selenium and omega-3 fatty acids, may improve thyroid-stimulating hormone (tsh) levels in women with subclinical hypothyroidism

to analyze in women diagnosed with subclinical hypothyroidism, the effects of consumption of dairy products rich in selenium and omega-3 on symptoms related to thyroid disease and blood lipid profile, inflammatory response, and fatty acid levels in the red blood cell membrane among others.

Eligibility criteria:
inclusion criteria: * diagnosis of subclinical hypothyroidism * tsh levels between 3 and 10 miu / l * normal levels of free triiodothyronine ( t3) and free thyroxine (t4) * without previous or current treatment with levothyroxine exclusion criteria: * thyroid surgery or reception of radioactive iodine in a previous period of 12 months * history of cardiovascular disease and / or thrombosis * established diagnosis or clinical suspicion of kidney or liver failure, chronic infections, blood diseases, type i diabetes and type ii diabetes * drug treatments that affect thyroid function (corticosteroids, amiodarone, propranolol, lithium) * statin treatment and / or hormone replacement therapy * adjuvant treatment with trace elements, vitamins or antidepressant and antipsychotic drugs * hospitalization for serious illness or elective surgery in the past 4 weeks * diseases and / or treatments that affect intestinal absorption (proton pump inhibitors) * pregnant, planning to become pregnant or breastfeeding women * consumption of ω-3 pufa type food supplements * intolerance and / or allergy to lactose and / or cow's milk proteins * any pathology that requires close control, advises against their participation or there is an inability to move independently * habitual residence outside the study's influence area * participation in another clinical trial with drugs, or in other experimental studies * refuse to sign the informed consent

Keywords: hypothyroidism selenium women
mind and body:a clinical trial evaluation of a smartphone app-based mindfulness intervention

Conditions: Psychological Stress; Psychological Distress; Rehabilitation

Summary: this study evaluates the use of a mobile-app delivered mindfulness-based intervention for supporting psychosocial resilience in aging patients undergoing rehabilitation treatment. half of the patients will receive the mobile-app, while the other half will receive the app 6 months later.

although, several mobile-app based mbts are available in the marketplace, there is scant evidence of high scientific rigor to support their therapeutic efficacy. furthermore, the tracking of wellness outcomes, stress resilience and functioning as a result of use of a therapeutic digital product is a challenging task requiring expertise in technology. in this study, the investigators aim to investigate not only the effectiveness of an app-based mbt in aging adults, but also the mechanisms of efficacy - i.e. the therapeutic effects - of app usage, including changes in, depression, anxiety, or mood and the acceptance of the app in older adult populations. the investigators also aim to measure the return on investment (roi) of mobile mindfulness on health services utilization. the study is a randomized controlled design with 1:1 equal allocation to treatment (experimental am app group) or control (treatment as usual). the investigators will recruit 82 participants in total. the experimental group will start the 4 week am app intervention immediately after randomization and baseline intervention questionnaires, while the wait-list control group will receive treatment as usual. assessments are conducted at four time point: at baseline (#1), post-intervention (#2), follow-up at 3 months post baseline (#3) and follow-up at 6 months post baseline (#4). the clinical champions that referred the patient to the study will complete brief surveys about the quality of their appointments with the patient at two time points: at baseline (#1) and post-intervention (#2). the waitlist control group will be granted access to the mindfulness intervention at 6 months post baseline.

Eligibility criteria:
inclusion criteria: 1. men and women over the age of 40. 2. admitted as in-patients. 3. access to a smart phone with data connection. 4. willing to give time for mindfulness practice. 5. sufficient ability to speak and read english. 6. willingness to be randomized into immediate or waitlist groups and complete all assessments. exclusion criteria: 1. any cognitive or mental impairment that would interfere with completing questionnaires or the intervention (\<6 on the brief screen for cognitive impairment) . 2. admitted to providence as an in-patient to long-term care or palliative care. 3. an existing smartphone app-based mindfulness practice consisting of one or more sessions per week.